Drugs / Exosurf
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT01203358 Comparator | Jan 1991 → Jan 1992 | bronchopulmonary dysplasia, fetal growth restriction | NICHD Neonatal Research Network | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exosurf | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01203358 ↗ |
| Known as | Exosurf Neonatal (Burroughs Wellcome Co.) | “Exosurf Neonatal (Burroughs Wellcome Co.)” NCT01203358 ↗ |
| Route | Other | “up to four intratracheal doses of either Exosurf Neonatal or Survanta” NCT01203358 ↗ |